Xeris Biopharma Holdings (STU:2B30) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2B30 Xeris Biopharma Holdings Inc STU:2B30
74 GF Score
Price €7.23
GF Value €4.55
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Xeris Biopharma Holdings Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Xeris Biopharma Holdings's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

STU:2B30 vs PAHC, PRGO, ALVO: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Xeris Biopharma Holdings's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xeris Biopharma Holdings Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Xeris Biopharma Holdings's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Xeris Biopharma Holdings's Margin of Safety % (DCF Earnings Based) falls into.


STU:2B30
74GF Score
Xeris Biopharma Holdings Inc STU:2B30
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xeris Biopharma Holdings (STU:2B30) Overvalued in 2026?

Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued. The current stock price of €7.23 is trading 58.9% above its estimated GF Value™ of €4.55. GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.

Key valuation signals for STU:2B30:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €4.55 vs. price of €7.23 (58.9% above fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the STU:2B30 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xeris Biopharma Holdings Business Description

Other Exchanges XERS:USA0A8E:UK
Address 1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
74GF Score

Get the complete analysis for STU:2B30

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.23
Price
€4.55
GF Value